U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Read more about U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Novartis Entresto® granted expanded indication in chronic heart failure by FDA Read more about Novartis Entresto® granted expanded indication in chronic heart failure by FDA
Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat) Read more about Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction Read more about US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status Read more about New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure Read more about Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash Read more about Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction Read more about Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction
Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial Read more about Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial
Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes Read more about Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes
